ME03523B - Inhibitori fosfoinozitid 3 kinaze sa dijelom koji vezuje cink - Google Patents
Inhibitori fosfoinozitid 3 kinaze sa dijelom koji vezuje cinkInfo
- Publication number
- ME03523B ME03523B MEP-2019-179A MEP2019179A ME03523B ME 03523 B ME03523 B ME 03523B ME P2019179 A MEP2019179 A ME P2019179A ME 03523 B ME03523 B ME 03523B
- Authority
- ME
- Montenegro
- Prior art keywords
- kinase inhibitor
- zinc binding
- binding fraction
- fraction
- zinc
- Prior art date
Links
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 230000004572 zinc-binding Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470849P | 2011-04-01 | 2011-04-01 | |
| US201161559489P | 2011-11-14 | 2011-11-14 | |
| EP16166266.3A EP3111938B1 (en) | 2011-04-01 | 2012-03-30 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03523B true ME03523B (me) | 2020-04-20 |
Family
ID=46931927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-179A ME03523B (me) | 2011-04-01 | 2012-03-30 | Inhibitori fosfoinozitid 3 kinaze sa dijelom koji vezuje cink |
| MEP-2016-116A ME02451B (me) | 2011-04-01 | 2012-03-30 | Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-116A ME02451B (me) | 2011-04-01 | 2012-03-30 | Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US8710219B2 (https=) |
| EP (2) | EP3111938B1 (https=) |
| JP (3) | JP6242331B2 (https=) |
| KR (2) | KR101902325B1 (https=) |
| CN (2) | CN105461736B (https=) |
| AU (1) | AU2012236367B2 (https=) |
| BR (1) | BR112013025340B1 (https=) |
| CA (1) | CA2830822C (https=) |
| CL (1) | CL2013002823A1 (https=) |
| CY (2) | CY1117785T1 (https=) |
| DK (2) | DK3111938T3 (https=) |
| EA (1) | EA022434B9 (https=) |
| ES (2) | ES2577982T3 (https=) |
| HR (2) | HRP20160545T1 (https=) |
| HU (2) | HUE028910T2 (https=) |
| IL (2) | IL228588A (https=) |
| LT (1) | LT3111938T (https=) |
| ME (2) | ME03523B (https=) |
| MX (1) | MX340577B (https=) |
| PE (1) | PE20141382A1 (https=) |
| PL (2) | PL2694075T3 (https=) |
| PT (2) | PT3111938T (https=) |
| RS (2) | RS59219B1 (https=) |
| SG (2) | SG10201602569RA (https=) |
| SI (2) | SI3111938T1 (https=) |
| SM (2) | SMT201900435T1 (https=) |
| TW (1) | TWI571469B (https=) |
| WO (1) | WO2012135571A1 (https=) |
| ZA (2) | ZA201307082B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA024252B1 (ru) | 2009-01-08 | 2016-08-31 | Кьюрис, Инк. | Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой |
| WO2012135571A1 (en) | 2011-04-01 | 2012-10-04 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| SG11201402004YA (en) | 2011-11-14 | 2014-05-29 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| CN104725301A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种1,2-二氢吡啶-2-酮衍生物的制备方法 |
| US10227347B2 (en) | 2015-04-21 | 2019-03-12 | Guizhou Bailing Group Pharmaceutical Co., Ltd. | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof |
| CA3030660C (en) * | 2016-07-19 | 2023-01-17 | National Institute Of Plant Genome Research | Mutated protein from burkholderia gladioli strain ngj1 against fungal pathogens |
| EA201991069A1 (ru) * | 2016-11-02 | 2019-10-31 | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
| US11406647B2 (en) * | 2017-11-06 | 2022-08-09 | Cold Spring Harbor Laboratory | Method and compositions for forming a copper-containing complex and uses thereof |
| CN113164466B (zh) | 2018-09-11 | 2025-07-08 | 柯瑞斯公司 | 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗 |
| EP3968215A1 (en) | 2020-09-09 | 2022-03-16 | Koninklijke Philips N.V. | Determining target object type and position |
| WO2023212574A1 (en) * | 2022-04-26 | 2023-11-02 | Olivia Szu Hsieh Lee Nakaya | Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| KR100774855B1 (ko) | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| CN100445276C (zh) | 2002-03-13 | 2008-12-24 | 詹森药业有限公司 | 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物 |
| MXPA04008797A (es) | 2002-03-13 | 2004-11-26 | Janssen Pharmaceutica Nv | Inhibidores de histona desacetilasa. |
| EA007099B1 (ru) | 2002-03-13 | 2006-06-30 | Янссен Фармацевтика Н. В. | Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы |
| HRP20040805A2 (en) | 2002-03-13 | 2005-04-30 | Janssen Pharmaceutica N.V. | Carbonylamino derivatives as novel inhibitors histone deacetylase |
| AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| EP1591446B1 (en) | 2003-01-29 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| CN101010298A (zh) | 2004-04-05 | 2007-08-01 | 默克Hdac研究有限责任公司 | 组蛋白脱乙酰酶抑制剂前药 |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| US7557112B2 (en) | 2004-10-08 | 2009-07-07 | Astellas Pharma Inc. | Aromatic-ring-fused pyrimidine derivative |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| JP5156392B2 (ja) | 2005-02-03 | 2013-03-06 | トポターゲット ユーケー リミテッド | Ｈｄａｃ阻害剤を用いる併用療法 |
| ES2553178T3 (es) | 2005-05-18 | 2015-12-04 | Janssen Pharmaceutica N.V. | Derivados sustituidos de aminopropenil piperidina o morfolina como nuevos inhibidores de histona deacetilasa |
| WO2007082874A1 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| US7888360B2 (en) | 2006-01-19 | 2011-02-15 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| DK1981871T3 (da) | 2006-01-19 | 2012-02-13 | Janssen Pharmaceutica Nv | Heterocyclylalkylderivater som hidtil ukendte inhibitorer af histondeacetylase |
| TW200801012A (en) * | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| TWI498332B (zh) | 2006-04-26 | 2015-09-01 | Hoffmann La Roche | 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物 |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| US20100016435A1 (en) | 2006-05-16 | 2010-01-21 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| WO2008033747A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| AU2007296746B2 (en) | 2006-09-11 | 2012-07-05 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| JP2010502741A (ja) | 2006-09-11 | 2010-01-28 | キュリス，インコーポレイテッド | Ｐｔｋインヒビターとしての亜鉛結合部分を含む置換２−インドリノン |
| AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US20080161320A1 (en) | 2006-09-11 | 2008-07-03 | Xiong Cai | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| CN105481788A (zh) | 2006-10-28 | 2016-04-13 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| MX2009005950A (es) * | 2006-12-07 | 2009-10-12 | Genentech Inc | Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso. |
| RU2470936C2 (ru) | 2006-12-07 | 2012-12-27 | Дженентек, Инк. | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения |
| US20100069458A1 (en) | 2007-02-15 | 2010-03-18 | Peter Wisdom Atadja | Combination of lbh589 with other therapeutic agents for treating cancer |
| CN101674833A (zh) | 2007-03-20 | 2010-03-17 | 柯瑞斯公司 | 含有锌结合半族的Raf激酶抑制剂 |
| WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
| WO2009036057A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Antiproliferative agents containing a zinc binding moiety |
| TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| US20090149511A1 (en) | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
| WO2009086012A1 (en) | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
| WO2010008847A2 (en) | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
| WO2009155659A1 (en) | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| US8196911B2 (en) | 2008-10-27 | 2012-06-12 | Honda Motor Co., Ltd. | Adjustable rate subframe mount |
| EA024252B1 (ru) * | 2009-01-08 | 2016-08-31 | Кьюрис, Инк. | Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| JP5709766B2 (ja) | 2009-03-12 | 2015-04-30 | ジェネンテック， インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用 |
| CA2776944A1 (en) | 2009-10-12 | 2011-05-12 | F. Hoffmann-La Roche Ag | Combinations of a pi3k inhibitor and a mek inhibitor |
| JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス，インコーポレイテッド | Ｋ−ｒａｓ変異を有する癌の治療 |
| WO2012135571A1 (en) * | 2011-04-01 | 2012-10-04 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| US20130102595A1 (en) | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| EA201991069A1 (ru) * | 2016-11-02 | 2019-10-31 | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом |
-
2012
- 2012-03-30 WO PCT/US2012/031361 patent/WO2012135571A1/en not_active Ceased
- 2012-03-30 US US13/435,062 patent/US8710219B2/en active Active
- 2012-03-30 KR KR1020137028748A patent/KR101902325B1/ko active Active
- 2012-03-30 DK DK16166266.3T patent/DK3111938T3/da active
- 2012-03-30 ME MEP-2019-179A patent/ME03523B/me unknown
- 2012-03-30 PT PT16166266T patent/PT3111938T/pt unknown
- 2012-03-30 EP EP16166266.3A patent/EP3111938B1/en active Active
- 2012-03-30 SM SM20190435T patent/SMT201900435T1/it unknown
- 2012-03-30 ME MEP-2016-116A patent/ME02451B/me unknown
- 2012-03-30 SI SI201231625T patent/SI3111938T1/sl unknown
- 2012-03-30 DK DK12764605.7T patent/DK2694075T3/en active
- 2012-03-30 JP JP2014502821A patent/JP6242331B2/ja active Active
- 2012-03-30 PL PL12764605.7T patent/PL2694075T3/pl unknown
- 2012-03-30 ES ES12764605.7T patent/ES2577982T3/es active Active
- 2012-03-30 TW TW101111283A patent/TWI571469B/zh active
- 2012-03-30 HU HUE12764605A patent/HUE028910T2/en unknown
- 2012-03-30 SG SG10201602569RA patent/SG10201602569RA/en unknown
- 2012-03-30 EP EP12764605.7A patent/EP2694075B1/en active Active
- 2012-03-30 CN CN201610034817.XA patent/CN105461736B/zh active Active
- 2012-03-30 SG SG2013070883A patent/SG193563A1/en unknown
- 2012-03-30 ES ES16166266T patent/ES2733128T3/es active Active
- 2012-03-30 CN CN201280026400.9A patent/CN103582483B/zh active Active
- 2012-03-30 MX MX2013011132A patent/MX340577B/es active IP Right Grant
- 2012-03-30 RS RSP20190842 patent/RS59219B1/sr unknown
- 2012-03-30 KR KR1020187026847A patent/KR20180108848A/ko not_active Ceased
- 2012-03-30 HU HUE16166266A patent/HUE045041T2/hu unknown
- 2012-03-30 RS RS20160457A patent/RS54903B1/sr unknown
- 2012-03-30 HR HRP20160545TT patent/HRP20160545T1/hr unknown
- 2012-03-30 EA EA201301114A patent/EA022434B9/ru unknown
- 2012-03-30 BR BR112013025340-1A patent/BR112013025340B1/pt active IP Right Grant
- 2012-03-30 PE PE2013002160A patent/PE20141382A1/es active IP Right Grant
- 2012-03-30 CA CA2830822A patent/CA2830822C/en active Active
- 2012-03-30 LT LTEP16166266.3T patent/LT3111938T/lt unknown
- 2012-03-30 PL PL16166266T patent/PL3111938T3/pl unknown
- 2012-03-30 AU AU2012236367A patent/AU2012236367B2/en active Active
- 2012-03-30 SI SI201230597A patent/SI2694075T1/sl unknown
- 2012-03-30 PT PT127646057T patent/PT2694075T/pt unknown
-
2013
- 2013-09-19 ZA ZA2013/07082A patent/ZA201307082B/en unknown
- 2013-09-29 IL IL228588A patent/IL228588A/en active IP Right Grant
- 2013-09-30 CL CL2013002823A patent/CL2013002823A1/es unknown
-
2014
- 2014-03-05 US US14/197,769 patent/US9249156B2/en active Active
- 2014-08-21 ZA ZA2014/06167A patent/ZA201406167B/en unknown
-
2015
- 2015-12-28 US US14/979,887 patent/US9657032B2/en active Active
-
2016
- 2016-06-16 SM SM201600179T patent/SMT201600179B/it unknown
- 2016-07-14 CY CY20161100683T patent/CY1117785T1/el unknown
- 2016-08-08 JP JP2016155625A patent/JP6275784B2/ja active Active
- 2016-10-30 IL IL248597A patent/IL248597B/en active IP Right Grant
-
2017
- 2017-04-25 US US15/496,318 patent/US10111864B2/en active Active
-
2018
- 2018-01-10 JP JP2018001910A patent/JP2018052987A/ja not_active Withdrawn
- 2018-10-03 US US16/150,845 patent/US10543197B2/en active Active
-
2019
- 2019-06-17 HR HRP20191091TT patent/HRP20191091T1/hr unknown
- 2019-07-17 CY CY20191100760T patent/CY1121825T1/el unknown
-
2020
- 2020-01-07 US US16/736,081 patent/US11135205B2/en active Active
-
2021
- 2021-09-09 US US17/470,410 patent/US11654136B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2504364I2 (lt) | Tiksliniai surišantys agentai prieš B7-H1 | |
| ME03523B (me) | Inhibitori fosfoinozitid 3 kinaze sa dijelom koji vezuje cink | |
| EP2385832A4 (en) | PHOSPHOINOSITIDE-3-KINASE-HEMMER WITH A ZINC-BONDING PART | |
| PL2536745T3 (pl) | Nowe immunoadhezyny CTLA4-IG | |
| SMT201500054B (it) | 2-Anilinobenzimidazolo-6-carbossammidi come agentianti-infiammattori | |
| CO6960518A2 (es) | Conjunto de desgaste | |
| BR112014000673A2 (pt) | conjunto de válvula | |
| BR112013033944A2 (pt) | combinação sinérgica | |
| EP2690309A4 (en) | TORQUE ROD | |
| BR112013023808A2 (pt) | montagem de ligação | |
| EP2670935A4 (en) | HINGE | |
| DK3517956T3 (da) | Modifikationsafhængige aktivitetsassayer | |
| BR112014007801A2 (pt) | conjunto de válvula | |
| BR112014011398A2 (pt) | presilha de engate | |
| DK2721152T3 (da) | Dimere bindingsproteiner baseret på modificerede ubiquitiner | |
| EP2557333A4 (en) | Dump truck | |
| DK3321261T3 (da) | Hedgehog-antagonister med zinkbindingsdele | |
| BR112013015829A2 (pt) | variantes de endoglucanase | |
| BR112013028388A2 (pt) | dobradiça | |
| CO6842023A2 (es) | Composición herbicida | |
| EP2529947A4 (en) | BINDER | |
| BR112014003094A2 (pt) | membro de redução de quantidade residual | |
| EP2701889A4 (en) | Bonding process | |
| BR112014015174A2 (pt) | conjunto de válvula | |
| DE112012000353A5 (de) | Nietverbindung |